The FDA received over 250 applications, and those selected will begin working with the FDA to release their products in real time to fight the opioid epidemic. The application process was open from June 1 through Sept. 30.
Here are the eight applicants that will receive FDA support:
1. Washington D.C.-based, Algometrx Inc. was selected for its rapid drug screen product in the drug monitoring category.
2. Alpharetta, Ga.-based Avanos was selected for a product withheld at the request of the company.
3. Jerusalem, Israel-based Brainsway Ltd was selected for its Brainsway Deep Transcranial Magnetic Stimulation Device in the opioid use disorder therapy category.
4. Sunnyvale, Calif.-based CognifiSense Inc. was selected for its Virtual Reality Neurophysiological Therapy in the pain therapy category.
5. Online- company iPill Dispenser was selected for its iPill Dispenser product in the medication dispensing category.
6. Irvine, Calif.-based Masimo Corp. was selected for a product withheld at the company’s request in the overdose therapy category.
7. Chicago-based Milliman was selected for its opioid prediction service in the diagnostic category.
8. Flower Mound, Texas-based ThermoTek Inc. was selected for its NanoTherm and VascuTherm systems in the pain therapy category.
More articles on opioids:
China will make fentanyl a controlled substance
Some marketplaces on UK’s dark web refuse to sell fentanyl
Bloomberg Philanthropies will gift $50M to combat opioid epidemic: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.